1.
|
Nelson WG, De Marzo AM and Isaacs WB:
Prostate cancer. N Engl J Med. 349:366–381. 2003. View Article : Google Scholar
|
2.
|
Nauseef JT and Henry MD:
Epithelial-to-mesenchymal transition in prostate cancer: paradigm
or puzzle? Nat Rev Urol. 8:428–439. 2011. View Article : Google Scholar : PubMed/NCBI
|
3.
|
Zhang J and Ma L: MicroRNA control of
epithelial-mesenchymal transition and metastasis. Cancer Metastasis
Rev. 31:653–662. 2012. View Article : Google Scholar : PubMed/NCBI
|
4.
|
Pencheva N and Tavazoie SF: Control of
metastatic progression by microRNA regulatory networks. Nat Cell
Biol. 15:546–554. 2013. View
Article : Google Scholar : PubMed/NCBI
|
5.
|
Peng X, Guo W, Liu T, et al:
Identification of miRs-143 and -145 that is associated with bone
metastasis of prostate cancer and involved in the regulation of
EMT. PLoS One. 6:e203412011. View Article : Google Scholar : PubMed/NCBI
|
6.
|
Tucci P, Agostini M, Grespi F, et al: Loss
of p63 and its microRNA-205 target results in enhanced cell
migration and metastasis in prostate cancer. Proc Natl Acad Sci
USA. 109:15312–15317. 2012. View Article : Google Scholar : PubMed/NCBI
|
7.
|
Liu C, Kelnar K, Liu B, et al: The
microRNA miR-34a inhibits prostate cancer stem cells and metastasis
by directly repressing CD44. Nat Med. 17:211–215. 2011. View Article : Google Scholar
|
8.
|
Saini S, Majid S, Yamamura S and Tabatabai
L: Regulatory role of mir-203 in prostate cancer progression and
metastasis. Clin Cancer Res. 17:5287–5298. 2011. View Article : Google Scholar : PubMed/NCBI
|
9.
|
Kong D, Li Y, Wang Z, Banerjee S, Ahmad A,
Kim HR and Sarkar FH: miR-200 regulates PDGF-D-mediated
epithelialmesenchymal transition, adhesion, and invasion of
prostate cancer cells. Stem Cells. 27:1712–1721. 2009. View Article : Google Scholar : PubMed/NCBI
|
10.
|
Sun D, Lee YS, Malhotra A, et al: miR-99
family of MicroRNAs suppresses the expression of prostate-specific
antigen and prostate cancer cell proliferation. Cancer Res.
71:1313–1324. 2011. View Article : Google Scholar : PubMed/NCBI
|
11.
|
Tong AW, Fulgham P, Jay C, et al: MicroRNA
profile analysis of human prostate cancers. Cancer Gene Ther.
16:206–216. 2009.PubMed/NCBI
|
12.
|
Giangreco AA, Vaishnav A, Wagner D,
Finelli A, et al: Tumor suppressor microRNAs, miR-100 and -125b,
are regulated by 1,25-dihydroxyvitamin D in primary prostate cells
and in patient tissue. Cancer Prev Res. 6:483–494. 2013. View Article : Google Scholar : PubMed/NCBI
|
13.
|
Leite KR, Sousa-Canavez JM, Reis ST,
Tomiyama AH, et al: Change in expression of miR-let7c, miR-100, and
miR-218 from high grade localized prostate cancer to metastasis.
Urol Oncol. 29:265–269. 2011. View Article : Google Scholar : PubMed/NCBI
|
14.
|
Leite KR, Tomiyama A, Reis ST,
Sousa-Canavez JM, Sañudo A, Camara-Lopes LH and Srougi M: MicroRNA
expression profiles in the progression of prostate cancer-from
high-grade prostate intraepithelial neoplasia to metastasis. Urol
Oncol. 31:796–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
15.
|
Porkka KP, Pfeiffer MJ, Waltering KK,
Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression
profiling in prostate cancer. Cancer Res. 67:6130–6135. 2007.
View Article : Google Scholar : PubMed/NCBI
|
16.
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
17.
|
Sethi S, Macoska J, Chen W and Sarkar FH:
Molecular signature of epithelial-mesenchymal transition (EMT) in
human prostate cancer bone metastasis. Am J Transl Res. 3:90–99.
2010.PubMed/NCBI
|
18.
|
Hugo H, Ackland ML, Blick T, Lawrence MG,
Clements JA, Williams ED and Thompson EW: Epithelial-mesenchymal
and mesenchymal-epithelial transitions in carcinoma progression. J
Cell Physiol. 213:374–383. 2007. View Article : Google Scholar : PubMed/NCBI
|
19.
|
Monteiro J and Fodde R: Cancer stemness
and metastasis: therapeutic consequences and perspectives. Eur J
Cancer. 46:1198–1203. 2010. View Article : Google Scholar : PubMed/NCBI
|
20.
|
Xia H and Hui KM: MicroRNAs involved in
regulating epithelial-mesenchymal transition and cancer stem cells
as molecular targets for cancer therapeutics. Cancer Gene Ther.
19:723–730. 2012. View Article : Google Scholar : PubMed/NCBI
|
21.
|
Huang S, Guo W, Tang Y, Ren D, Zou X and
Peng X: miR-143 and miR-145 inhibit stem cell characteristics of
PC-3 prostate cancer cells. Oncol Rep. 28:1831–1837.
2012.PubMed/NCBI
|
22.
|
Janas MM, Wang B, Harris AS, et al:
Alternative RISC assembly: binding and repression of microRNA-mRNA
duplexes by human Ago proteins. RNA. 18:2041–2055. 2012. View Article : Google Scholar
|
23.
|
Cheng N, Li Y and Han ZG: Argonaute2
promotes tumor metastasis by way of up-regulating focal adhesion
kinase expression in hepatocellular carcinoma. Hepatology.
57:1906–1918. 2013. View Article : Google Scholar
|
24.
|
Cheloufi S, Dos Santos CO, Chong MM and
Hannon GJ: A dicer-independent miRNA biogenesis pathway that
requires Ago catalysis. Nature. 465:584–589. 2010. View Article : Google Scholar : PubMed/NCBI
|
25.
|
Zhou Y, Chen L, Barlogie B, Stephens O, et
al: High-risk myeloma is associated with global elevation of miRNAs
and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci USA.
107:7904–7909. 2010. View Article : Google Scholar : PubMed/NCBI
|
26.
|
Yoo NJ, Hur SY, Kim MS, Lee JY and Lee SH:
Immunohisto-chemical analysis of RNA-induced silencing
complex-related proteins AGO2 and TNRC6A in prostate and esophageal
cancers. APMIS. 118:271–276. 2010. View Article : Google Scholar : PubMed/NCBI
|
27.
|
Sand M, Skrygan M, Georgas D, et al:
Expression levels of the microRNA maturing microprocessor complex
component DGCR8 and the RNA-induced silencing complex (RISC)
components argonaute-1, argonaute-2, PACT, TARBP1, and TARBP2 in
epithelial skin cancer. Mol Carcinog. 51:916–922. 2012. View Article : Google Scholar
|
28.
|
Naoghare PK, Tak YK, Kim MJ, Han E and
Song JM: Knock-down of Argonaute 2 (AGO2) induces apoptosis in
myeloid leukaemia cells and inhibits siRNA-mediated silencing of
transfected oncogenes in HEK-293 cells. Basic Clin Pharmacol
Toxicol. 109:274–282. 2011. View Article : Google Scholar : PubMed/NCBI
|
29.
|
Shekar PC, Naim A, Sarathi DP and Kumar S:
Argonaute-2-null embryonic stem cells are retarded in self-renewal
and differentiation. J Biosci. 36:649–657. 2011. View Article : Google Scholar : PubMed/NCBI
|
30.
|
Mo YY and Beck WT: Association of human
DNA topoisomerase IIalpha with mitotic chromosomes in mammalian
cells is independent of its catalytic activity. Exp Cell Res.
252:50–62. 1999. View Article : Google Scholar : PubMed/NCBI
|
31.
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(T) (-Delta Delta C) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
32.
|
Majid S, Dar AA, Saini S, Deng G, et al:
MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in
bladder cancer. PLoS One. 8:e676862013. View Article : Google Scholar : PubMed/NCBI
|
33.
|
Huang J, Egger M, Grizzle W and McNally L:
MicroRNA-100 regulates IGF1-receptor expression in metastatic
pancreatic cancer cells. Biotech Histochem. 88:397–402. 2013.
View Article : Google Scholar : PubMed/NCBI
|
34.
|
Wang G, Chen L, Meng J, Chen M, Zhuang L
and Zhang L: Overexpression of microRNA-100 predicts an unfavorable
prognosis in renal cell carcinoma. Int Urol Nephrol. 45:373–379.
2013. View Article : Google Scholar : PubMed/NCBI
|
35.
|
Shimamura T, Imoto S, Shimada Y, et al: A
novel network profiling analysis reveals system changes in
epithelial-mesenchymal transition. PLoS One. 6:e208042011.
View Article : Google Scholar : PubMed/NCBI
|
36.
|
Wotschofsky Z, Liep J, Meyer HA, Jung M,
et al: Identification of metastamirs as metastasis-associated
microRNAs in clear cell renal cell carcinomas. Int J Biol Sci.
8:1363–1374. 2012. View Article : Google Scholar : PubMed/NCBI
|
37.
|
Huang L, Lin JX, Yu YH, Zhang MY, Wang HY
and Zheng M: Downregulation of six microRNAs is associated with
advanced stage, lymph node metastasis and poor prognosis in small
cell carcinoma of the cervix. PLoS One. 7:e337622012. View Article : Google Scholar : PubMed/NCBI
|
38.
|
Li L, Yu C, Gao H and Li Y: Argonaute
proteins: potential biomarkers for human colon cancer. BMC Cancer.
10:382010. View Article : Google Scholar : PubMed/NCBI
|
39.
|
Adams BD, Claffey KP and White BA:
Argonaute-2 expression is regulated by epidermal growth factor
receptor and mitogen-activated protein kinase signaling and
correlates with a transformed phenotype in breast cancer cells.
Endocrinology. 150:14–23. 2009. View Article : Google Scholar
|
40.
|
Vaksman O, Hetland TE, Trope’ CG, Reich R
and Davidson B: Argonaute, Dicer, and Drosha are up-regulated along
tumor progression in serous ovarian carcinoma. Hum Pathol.
43:2062–2069. 2012. View Article : Google Scholar : PubMed/NCBI
|
41.
|
Chang SS, Smith I, Glazer C, Hennessey P
and Califano JA: EIF2C is overexpressed and amplified in head and
neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec.
72:337–343. 2010. View Article : Google Scholar : PubMed/NCBI
|
42.
|
Iosue I, Quaranta R, Masciarelli S, et al:
Argonaute 2 sustains the gene expression program driving human
monocytic differentiation of acute myeloid leukemia cells. Cell
Death Dis. 4:e9262013. View Article : Google Scholar
|
43.
|
Siemens H, Jackstadt R, Hünten S, Kaller
M, Menssen A, Götz U and Hermeking H: miR-34 and SNAIL form a
double-negative feedback loop to regulate epithelial-mesenchymal
transitions. Cell Cycle. 10:4256–4271. 2011. View Article : Google Scholar : PubMed/NCBI
|
44.
|
Kim T, Veronese A, Pichiorri F, Lee TJ, et
al: p53 regulates epithelial-mesenchymal transition through
microRNAs targeting ZEB1 and ZEB2. J Exp Med. 208:875–883. 2011.
View Article : Google Scholar : PubMed/NCBI
|
45.
|
Ferracin M, Bassi C, Pedriali M, et al:
miR-125b targets erythropoietin and its receptor and their
expression correlates with metastatic potential and ERBB2/HER2
expression. Mol Cancer. 12:1302013. View Article : Google Scholar : PubMed/NCBI
|
46.
|
Li Y, Chao Y, Fang Y, et al: MTA1 promotes
the invasion and migration of non-small cell lung cancer cells by
downregulating miR-125b. J Exp Clin Cancer Res. 32:332013.
View Article : Google Scholar : PubMed/NCBI
|
47.
|
Rajabi H, Joshi MD, Jin C, Ahmad R and
Kufe D: Androgen receptor regulates expression of the MUC1-C
oncoprotein in human prostate cancer cells. Prostate. 71:1299–1308.
2011.PubMed/NCBI
|
48.
|
Liang L, Wong CM, Ying Q, et al:
MicroRNA-125b suppressesed human liver cancer cell proliferation
and metastasis by directly targeting oncogene LIN28B2. Hepatology.
52:1731–1740. 2010. View Article : Google Scholar : PubMed/NCBI
|
49.
|
Scott GK, Goga A, Bhaumik D, Berger CE,
Sullivan CS and Benz CC: Coordinate suppression of ERBB2 and ERBB3
by enforced expression of microRNA miR-125a or miR-125b. J Biol
Chem. 282:1479–1486. 2007. View Article : Google Scholar : PubMed/NCBI
|
50.
|
Nair R, Roden DL, Teo WS, et al: c-Myc and
Her2 cooperate to drive a stem-like phenotype with poor prognosis
in breast cancer. Oncogene. Sep 23–2013.(Epub ahead of print).
View Article : Google Scholar
|
51.
|
Cheng JC, Qiu X, Chang HM and Leung PC:
HER2 mediates epidermal growth factor-induced down-regulation of
E-cadherin in human ovarian cancer cells. Biochem Biophys Res
Commun. 434:81–86. 2013. View Article : Google Scholar : PubMed/NCBI
|
52.
|
Kim IY, Yong HY, Kang KW and Moon A:
Overexpression of ErbB2 induces invasion of MCF10A human breast
epithelial cells via MMP-9. Cancer Lett. 275:227–233. 2009.
View Article : Google Scholar : PubMed/NCBI
|
53.
|
Kim BS, Im YB, Jung SJ, Park CH and Kang
SK: Argonaute2 regulation for K+ channel-mediated human
adipose tissue-derived stromal cells self-renewal and survival in
nucleus. Stem Cells Dev. 21:1736–1748. 2012.PubMed/NCBI
|
54.
|
Shen XH, Han YJ, Cui XS and Kim NH: Ago2
and GW182 expression in mouse preimplantation embryos: a link
between microRNA biogenesis and GW182 protein synthesis. Reprod
Fertil Dev. 22:634–643. 2010. View Article : Google Scholar : PubMed/NCBI
|
55.
|
Carmell MA, Xuan Z, Zhang MQ and Hannon
GJ: The Argonaute family: tentacles that reach into RNAi,
developmental control, stem cell ––maintenance, and tumorigenesis.
Genes Dev. 16:2733–2742. 2002.PubMed/NCBI
|